Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Adverse effects == The use of clinafloxacin is associated with drug-induced light sensitivity (phototoxicity) and low blood sugar. Diarrhea has also been reported. The phototoxicity with clinafloxacin has been more associated with oral dosing as compared to intravenous dosing, though the studies that described this were subject to confounding by study site (that is, patients that received intravenous clinafloxacin were less mobile, and thereby received less sunlight exposure). The mechanism for clinafloxacin's phototoxicity involves the chlorine atom at position 8. In the presence of ultraviolet light, the chemical structure of clinafloxacin is degraded, resulting in the formation of toxic, reactive oxygen species that can damage cellular structures—including DNA. For this reason clinafloxacin can also be classified as a photocarcinogen (a chemical that can cause light-induced cancer), though the risk of developing cancer in humans taking the medication is small. The mechanism for clinafloxacin's effect on blood glucose is thought to involve stimulation of the pancreatic beta cells, which produce insulin (a hormone that lowers blood glucose levels). The symptoms of clinafloxacin overdose are unknown.
87Rb, 187Re, 176Lu, 232Th, and 238U have half-lives long enough that their decay is limited over geological time scales; 40K and 235U have shorter half-lives and are hence severely depleted, but are still long-lived enough to remain present in significant amount on Earth. The longest-lived isotope not proven to be primordial is 146Sm, which has a half-life of 9.20×107 years, followed by 244Pu (8.13×107 years) and 92Nb (3.47×107 years). 244Pu was reported to exist in nature as a primordial nuclide in 1971, but this detection could not be confirmed by further studies in 2012 and 2022. Taking into account that all these nuclides must exist for at least 4.58×109 years, 146Sm must survive 50 half-lives (and hence be reduced by 250 ≈ 1×1015), 244Pu must survive 57 (and be reduced by a factor of 257 ≈ 1×1017), and 92Nb must survive 130 (and be reduced by 2130 ≈ 1×1039). Mathematically, considering the likely initial abundances of these nuclides, primordial 146Sm and 244Pu should persist somewhere within the Earth today, even if they are not identifiable in the relatively minor portion of the Earth's crust available to human assays, while 92Nb and all shorter-lived nuclides should not. Nuclides such as 92Nb that were present in the primordial solar nebula but have long since decayed away completely are termed extinct radionuclides if they have no other means of being regenerated. As for 244Pu, calculations suggest that as of 2022, sensitivity limits were about one order of magnitude away from detecting it as a primordial nuclide.
Insulin glulisine is a rapid-acting modified form of insulin used to treat diabetes. It differs from human insulin by replacing the amino acid asparagine at position B3 with lysine and the lysine at position B29 with glutamic acid. When injected subcutaneously, it enters the bloodstream faster than regular human insulin (RHI). It was developed by Sanofi. The most common side effect is hypoglycemia (low blood glucose levels). Insulin glulisine was approved for medical use in the United States and the European Union in 2004. It is currently patented by Sanofi, and is therefore only produced by said company under the brand name Apidra.
Recent research has expanded understanding of snake venom LAAOs (sv-LAAOs), revealing their role in venom-induced tissue damage through oxidative stress and induction of cell death pathways such as autophagy, apoptosis, and necrosis. Structural studies have clarified their three-domain organization and active site variability, which underlie substrate specificity and functional diversity. In addition to their antimicrobial properties, sv-LAAOs exhibit selective cytotoxicity against tumor cells, making them a subject of growing interest for therapeutic development.
=== Bank buildings === The Bowery Savings Bank was chartered in May 1834, when the Bowery was an upscale residential street, and grew with the rising prosperity of the city. Its 1893 headquarters building at 130 Bowery is an official New York City designated landmark, as is the 1920s domed Citizens Savings Bank.
Sources: en.wikipedia.org
Allyn Taylor International Prize in Medicine for Diabetes, Toronto, Canada (2002) Manpei Suzuki International Prize for Top Diabetes Researcher Worldwide (Inaugural Recipient), Tokyo, Japan (2009) Hans Falk Memorial Lecture, National Institute of Environmental Health Science (2009) Presidential Lecture, Memorial Sloan Kettering Cancer Institute, New York (2010) Alpha Omega Alpha Visiting Professor, Columbia University Medical School, New York, NY (2010) Frontiers in Science Award, American Association of Clinical Endocrinologists (2010) Cockrell Foundation Award in Basic and Clinical Research, Houston, TX (2010) Distinguished Leader in Insulin Resistance, World Congress of Insulin Resistance in Diabetes and Cardiovascular Disease, Los Angeles, CA (2010) David Murdock Dole Honorary Lecture, Mayo Clinic-Karolinska, Nobel Forum, Stockholm, Sweden (2011) Wallace H. Coulter Award, American Association of Clinical Chemistry (2013) Helmholtz Diabetes Research Lifetime Achievement Award, Munich, Germany (2013) Honorary Adjunct Member, Max Planck Institute, Cologne, Germany (2014) Ipsen Foundation Prize in Endocrine Regulation (2015) Harold Hamm Prize in Diabetes (2015) Wolf Prize in Medicine, Jerusalem, Israel (2016)
==== Extracellular proteases ==== The green microalgae Chlamydomonas coccoides and Dunaliella sp. and chlorella sphaerkii (a unicellular marine chlorophyte) were found to produce extracellular proteases. The diatom Chaetoceros didymus releases substantial amounts of proteases into the medium, this production is induced by the presence of the lytic bacterium Kordia algicida and is connected to the resistance of this alga against the effects of this bacterium. Some proteases are of functional importance in viral life cycles, thus being attractive targets for drug development.
Valve canceled a port of Half-Life for MacOS, developed by Logicware, in 2000. Newell cited several shortcomings such as the lack of an auto-updater and the lack of Team Fortress Classic, and in general was worried that Mac players would be "second-class customers" due to Valve being unable to justify ongoing updates to the Mac port. Rebecca Heineman, the co-founder of Logicware, said that the main reason that Valve canceled the Mac port was that Apple had angered Valve by misrepresenting sales projections (by an order of magnitude). She said the port was complete and three weeks from release when it was canceled due to preorder numbers being much lower than Valve expected. Valve released ports for OS X and Linux in 2013. Captivation Digital Laboratories and Gearbox Software developed a port of Half-Life for the Dreamcast, with new character models and textures and an exclusive expansion, Blue Shift. Following the cancellations of several third-party games in the wake of Sega's decision to discontinue the Dreamcast in March 2001, Sierra cancelled the port weeks before its scheduled release in June, citing "changing marketing conditions". Blue Shift was ported to Windows. The Dreamcast port became the basis of the Half-Life port for PlayStation 2, released in late 2001. This version added competitive play and a co-op expansion, Half-Life: Decay. In 2004, Valve released Half-Life: Source, a version of Half-Life ported to their new game engine, Source. It adds ragdoll physics, advanced water effects, and 5.1 surround sound.
SA biosynthesis is increased via isochorismate synthase (ICS) and phenylalanine ammonia-lyase (PAL) pathway in plastids. It was observed that during plant-microbe interactions, as part of the defense mechanisms, SA is initially accumulated at the local infected tissue and then spread all over the plant to induce systemic acquired resistance at non-infected distal parts of the plant. Therefore with increased internal concentration of SA, plants were able to build resistant barriers for pathogens and other adverse environmental conditions.
In their second publication on nuclear fission, Hahn and Strassmann used the term Uranspaltung (uranium fission) for the first time, and predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction. This was shown to be the case by Frédéric Joliot and his team in March 1939. Edwin McMillan and Philip Abelson used the cyclotron at the Berkeley Radiation Laboratory to bombard uranium with neutrons, and were able to identify an isotope with a 23-minute half-life that was the daughter of uranium-239, and therefore the real element 93, which they named neptunium. "There goes a Nobel Prize", Hahn remarked. At the KWIC, Kurt Starke independently produced element 93, using only the weak neutron sources available there. Hahn and Strassmann then began researching its chemical properties. They knew that it should decay into the real element 94, which according to the latest version of the liquid drop model of the nucleus propounded by Bohr and John Archibald Wheeler, would be even more fissile than uranium-235, but were unable to detect its radioactive decay. They concluded that it must have an extremely long half-life, perhaps millions of years. Part of the problem was that they still believed that element 94 was a platinoid, which confounded their attempts at chemical separation.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.